BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 33629605)

  • 21. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis.
    Gopal AK; Gooley TA; Maloney DG; Petersdorf SH; Eary JF; Rajendran JG; Bush SA; Durack LD; Golden J; Martin PJ; Matthews DC; Appelbaum FR; Bernstein ID; Press OW
    Blood; 2003 Oct; 102(7):2351-7. PubMed ID: 12750161
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The potential benefit of allogeneic over autologous transplantation in patients with very early relapsed and refractory follicular lymphoma with prior remission duration of ≤12 months.
    Lunning MA; Migliacci JC; Hilden P; Devlin SM; Castro-Malaspina H; Giralt S; Perales MA; Zelenetz AD; Moskowitz CH; Sauter CS
    Br J Haematol; 2016 Apr; 173(2):260-4. PubMed ID: 26847389
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
    Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Follicular lymphoma: 2020 update on diagnosis and management.
    Freedman A; Jacobsen E
    Am J Hematol; 2020 Mar; 95(3):316-327. PubMed ID: 31814159
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Classic Hodgkin lymphoma developing early after treatment of follicular lymphoma].
    Ueda N; Hashimoto K; Yamazoe Y; Adachi Y; Kihara R; Kuwabara K; Fujino M; Watamoto K
    Rinsho Ketsueki; 2020; 61(1):39-43. PubMed ID: 32023601
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cellular Therapy in Follicular Lymphoma: Autologous Stem Cell Transplantation, Allogeneic Stem Cell Transplantation, and Chimeric Antigen Receptor T-cell Therapy.
    Okosun J; Montoto S
    Hematol Oncol Clin North Am; 2020 Aug; 34(4):701-714. PubMed ID: 32586575
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary cutaneous non-Hodgkin's lymphoma with aggressive histology: inferior outcome is associated with peripheral T-cell type and elevated lactate dehydrogenase, but not extent of cutaneous involvement.
    Visco C; Medeiros LJ; Jones D; Smith T; Rodriguez MA; McLaughlin P; Romaguera J; Cabanillas F; Sarris AH
    Ann Oncol; 2002 Aug; 13(8):1290-9. PubMed ID: 12181254
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autologous hematopoietic stem cell transplantation for relapsed follicular lymphoma: safety profile and clinical outcome in a single-center experience.
    Helbig G; Krawczyk-Kulis M; Kopinska A; Liwoch R; Kyrcz-Krzemien S
    Med Oncol; 2014 Dec; 31(12):310. PubMed ID: 25373321
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Primary follicular lymphoma of the gastrointestinal tract: a clinical and pathologic study of 26 cases.
    Shia J; Teruya-Feldstein J; Pan D; Hegde A; Klimstra DS; Chaganti RS; Qin J; Portlock CS; Filippa DA
    Am J Surg Pathol; 2002 Feb; 26(2):216-24. PubMed ID: 11812943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma.
    Sabloff M; Atkins HL; Bence-Bruckler I; Bredeson C; Fergusson D; Genest P; Hopkins H; Hutton B; Mcdiarmid S; Huebsch LB
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):956-64. PubMed ID: 17640600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: effect of histological grade and Follicular International Prognostic Index.
    Vose JM; Bierman PJ; Loberiza FR; Lynch JC; Bociek GR; Weisenburger DD; Armitage JO
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):36-42. PubMed ID: 18158959
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prolonged clinical remissions in patients with relapsed or refractory follicular lymphoma treated with autologous stem cell transplantation incorporating rituximab.
    Berinstein NL; Bhella S; Pennell NM; Cheung MC; Imrie KR; Spaner DE; Milliken V; Zhang L; Hewitt K; Boudreau A; Reis MD; Chesney A; Good D; Ghorab Z; Hicks LK; Piliotis E; Buckstein R
    Ann Hematol; 2015 May; 94(5):813-23. PubMed ID: 25567231
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Follicular lymphoma: emerging therapeutic strategies.
    Kenkre VP; Kahl BS
    Expert Rev Hematol; 2010 Aug; 3(4):485-95. PubMed ID: 21083037
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma.
    Lazzarino M; Arcaini L; Bernasconi P; Alessandrino EP; Gargantini L; Cairoli R; Orlandi E; Astori C; Brusamolino E; Pagnucco G; Colombo AA; Calatroni S; Iacona I; Regazzi MB; Morra E
    Br J Haematol; 2002 Jan; 116(1):229-35. PubMed ID: 11841421
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project.
    Evens AM; Vanderplas A; LaCasce AS; Crosby AL; Nademanee AP; Kaminski MS; Abel GA; Millenson M; Czuczman MS; Rodriguez MA; Niland J; Zelenetz AD; Gordon LI; Friedberg JW
    Cancer; 2013 Oct; 119(20):3662-71. PubMed ID: 23921646
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Follicular non-Hodgkin lymphoma: long-term results of stem-cell transplantation.
    Barr PM; Lazarus HM
    Curr Opin Oncol; 2008 Sep; 20(5):502-8. PubMed ID: 19106651
    [TBL] [Abstract][Full Text] [Related]  

  • 37. T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma.
    Thomson KJ; Morris EC; Milligan D; Parker AN; Hunter AE; Cook G; Bloor AJ; Clark F; Kazmi M; Linch DC; Chakraverty R; Peggs KS; Mackinnon S
    J Clin Oncol; 2010 Aug; 28(23):3695-700. PubMed ID: 20606089
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful treatment of isolated cutaneous relapse of follicular lymphoma with rituximab.
    Ferrer A; López-Guillermo A; Montoto S; Estrach T; Colomo L; Montserrat E
    Ann Hematol; 2001 Aug; 80(8):479-81. PubMed ID: 11563595
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors.
    Klyuchnikov E; Bacher U; Kröger NM; Hari PN; Ahn KW; Carreras J; Bachanova V; Bashey A; Cohen JB; D'Souza A; Freytes CO; Gale RP; Ganguly S; Hertzberg MS; Holmberg LA; Kharfan-Dabaja MA; Klein A; Ku GH; Laport GG; Lazarus HM; Miller AM; Mussetti A; Olsson RF; Slavin S; Usmani SZ; Vij R; Wood WA; Maloney DG; Sureda AM; Smith SM; Hamadani M
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2091-2099. PubMed ID: 26253007
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
    William BM; Allen MS; Loberiza FR; Bociek RG; Bierman PJ; Armitage JO; Vose JM
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):536-42. PubMed ID: 24434781
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.